It's not complicated. It is what Gerald has be
Post# of 30066
(Total Views: 615)
Posted On: 10/25/2019 12:34:13 PM
It's not complicated.
It is what Gerald has been working towards from the beginning.
Despite all the lies that have been spread, his main goal was to "have a clear path towards delivering value for the various Amarantus stakeholders," and now it's as close as he's been in getting that done.
No one is waking up with cash in their accounts and no shares.
"Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced it has entered into a binding term sheet to license its therapeutic assets to Emerald Organic Growth, Inc. (OTCPK: EMOR) (“Emerald” or EMOR), a fully-integrated, CBD-based health sciences company launching branded products via its nationwide distribution channels. Amarantus will receive Emerald Preferred Stock to be valued at a minimum of $100M in 2022, and up to double digit royalties (in addition to passthrough royalties and milestones) in exchange for worldwide, exclusive development and commercial rights to eltoprazine, engineered skin substitute (ESS), mesencephalic astrocyte-derived neurotrophic factor (MANF) and PhenoGuard."
It's been in the name the whole time. He set up a holding company for a reason.
The goal is still to Reg A up to the big board and own shares in a Bioscience Holding company. Will the Call letters continue to be AMBS... we'll see, but whatever shares of AMBS will convert to the new symbol if there is a new symbol.
Will the shares be a clean 1:1 , that I have zero clue. I personally would be quite happy if that ends up being the case.
So AMBS (let's say it's still that) will just be a company that gets paid as all of it's products hit milestones and move to market. The team will be on board and continue to move al of them forward at different stages.
It just won't be funded by Amarantus any longer.
Which has been the ultimate goal from day one. Yes, it's been a long long road with incredible bumps along the way and we are still not done. There is a lot of work that needs to be completed.
But a clear path is in sight. It's a matter of the absolute closing of this deal and the uplist of Todos as well.
How much cash will be generated and when will the Reg A happen?
TBD
For all 3 to happen before the year is up is ambitious....
But you can spell ambitious without AMBS... whatever, laugh, don't laugh at that, or own shares and laugh all the way to the bank "once this gets done."
I don't expect all this to happen by Jan. 1. It would be great, but another quarter wouldn't hurt after all this time, right.
The plan has been the same since day one.
Now, it's time to see it unfold (MANF humor).
Aloha
It is what Gerald has been working towards from the beginning.
Despite all the lies that have been spread, his main goal was to "have a clear path towards delivering value for the various Amarantus stakeholders," and now it's as close as he's been in getting that done.
No one is waking up with cash in their accounts and no shares.
"Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced it has entered into a binding term sheet to license its therapeutic assets to Emerald Organic Growth, Inc. (OTCPK: EMOR) (“Emerald” or EMOR), a fully-integrated, CBD-based health sciences company launching branded products via its nationwide distribution channels. Amarantus will receive Emerald Preferred Stock to be valued at a minimum of $100M in 2022, and up to double digit royalties (in addition to passthrough royalties and milestones) in exchange for worldwide, exclusive development and commercial rights to eltoprazine, engineered skin substitute (ESS), mesencephalic astrocyte-derived neurotrophic factor (MANF) and PhenoGuard."
It's been in the name the whole time. He set up a holding company for a reason.
The goal is still to Reg A up to the big board and own shares in a Bioscience Holding company. Will the Call letters continue to be AMBS... we'll see, but whatever shares of AMBS will convert to the new symbol if there is a new symbol.
Will the shares be a clean 1:1 , that I have zero clue. I personally would be quite happy if that ends up being the case.
So AMBS (let's say it's still that) will just be a company that gets paid as all of it's products hit milestones and move to market. The team will be on board and continue to move al of them forward at different stages.
It just won't be funded by Amarantus any longer.
Which has been the ultimate goal from day one. Yes, it's been a long long road with incredible bumps along the way and we are still not done. There is a lot of work that needs to be completed.
But a clear path is in sight. It's a matter of the absolute closing of this deal and the uplist of Todos as well.
How much cash will be generated and when will the Reg A happen?
TBD
For all 3 to happen before the year is up is ambitious....
But you can spell ambitious without AMBS... whatever, laugh, don't laugh at that, or own shares and laugh all the way to the bank "once this gets done."
I don't expect all this to happen by Jan. 1. It would be great, but another quarter wouldn't hurt after all this time, right.
The plan has been the same since day one.
Now, it's time to see it unfold (MANF humor).
Aloha
(8)
(0)